Finally, we performed differential expression analysis on EGFR inhibitor sensitivity genes and the predicted methylation sites, and found some examples that displayed the changes in methylation level of predicted methylation sites, which may lead to changes in the expression level of corresponding responsive genes, and then affect the effectiveness of drugs in lung cancer. The gene discussed is EGFR; the disease is lung cancer.